Welcome to our dedicated page for 60 degrees pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 degrees pharmaceuticals stock.
60 Degrees Pharmaceuticals, Inc. (SXTP) is a clinical-stage company advancing novel therapies for infectious diseases, including its FDA-approved malaria prophylaxis ARAKODA. This news hub provides investors and healthcare stakeholders with verified updates on the company's scientific progress and operational developments.
Access timely announcements including clinical trial results, regulatory milestones, research partnerships, and strategic initiatives. Our curated collection ensures transparent tracking of SXTP's work in malaria prevention, tick-borne illness therapies, and antifungal/viral treatment pipelines.
Key updates cover FDA communications, trial phase transitions, academic collaborations, and market expansion efforts. The resource is particularly valuable for monitoring the company's progress in repurposing tafenoquine for emerging indications like babesiosis.
Bookmark this page for centralized access to SXTP's latest scientific advancements and corporate announcements. For comprehensive tracking of infectious disease treatment innovations, consider subscribing to our regulatory update alerts.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced a registered direct offering priced at-the-market under Nasdaq rules, consisting of 1,021,549 shares of common stock at $1.021 per share. The company will also issue unregistered short-term warrants in a concurrent private placement to purchase up to 2,043,098 shares at $0.771 per share, exercisable for 24 months upon issuance.
The offering, expected to close around January 30, 2025, will generate gross proceeds of $1.043 million before deducting fees and expenses. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has received IRB approval for a Phase II clinical study to evaluate ARAKODA® (tafenoquine) in treating chronic babesiosis. The open-label study (NCT06656351) will assess the drug's efficacy and safety over 90 days in outpatient settings, targeting patients with presumptive chronic babesiosis who have experienced significant functional impairment for at least six months.
Patient enrollment is scheduled to begin in Q3 2025. The company estimates the total cumulative addressable market through December 2035 (U.S. patent protection end) exceeds 400,000 patients. The study aims to address an unmet medical need, as there are currently no approved treatment options for chronic babesiosis, a condition that is emerging in new regions of the U.S.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has initiated enrollment in an expanded access clinical study for tafenoquine in treating persistent babesiosis. The study aims to confirm the drug's effectiveness in patients who have failed standard care treatment and are at high relapse risk.
Recent clinical case studies showed tafenoquine achieved an 80% cure rate in five high-risk patients with persistent, relapsing babesiosis who failed prior treatments. Babesiosis, a potentially life-threatening tick-borne disease transmitted by the black-legged tick, shows increasing incidence in the Northeast U.S.
The company estimates the total cumulative accessible market through December 2035 (U.S. patent protection end) may exceed 400,000 patients. While tafenoquine is currently approved as ARAKODA for malaria prophylaxis, it has not been proven effective or received FDA approval for babesiosis treatment or prevention.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) and Tufts Medical Center have signed a Patent License Agreement to develop and commercialize tafenoquine for babesiosis treatment and prevention. The agreement establishes joint patent ownership, with 60 Degrees leading global commercialization efforts and holding exclusive rights. Tufts MC will receive royalties on net sales while retaining research rights. The collaboration aims to address an unmet medical need, as tafenoquine could potentially become the first prophylaxis available for babesiosis, a tick-borne disease affecting red blood cells. The agreement follows initial research collaboration between both organizations, resulting in U.S. Provisional Patent Application No. 63/461,060.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has expanded its tafenoquine clinical trial for babesiosis to Brigham and Women's Hospital in Boston. The double-blind, placebo-controlled study will evaluate tafenoquine combined with standard treatment for hospitalized babesiosis patients. The trial is also ongoing at Tufts Medical Center, Yale University, and Rhode Island Hospital.
The study aims to recruit 24-33 patients in summer 2025, with an interim analysis expected in early 2026. The main endpoints are time to sustained clinical resolution of symptoms and molecular cure. Recent case studies suggest tafenoquine with standard care shows high cure rates in immunosuppressed patients with relapsing babesiosis. The company estimates the total accessible market through December 2035 could exceed 400,000 patients.
VSee Health (Nasdaq:VSEE) was featured on Bloomberg TV's RedChip Small Stocks, Big Money show. In the interview, co-CEO Imo Aisiku discussed the company's position in the $787 billion telehealth market. VSee's AI telehealth platform processes over 1.5M HIPAA-compliant video encounters monthly and has been deployed in over 50 countries. The company serves major clients including NASA, US Department of Health and Human Services, McKesson, Magellan, DaVita, GE, and Qatar's healthcare system.
60 Degrees Pharmaceuticals (SXTP) and Can-Fite BioPharma (CANF) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV on November 23 at 7 p.m. ET. The program, reaching approximately 73 million U.S. homes, will include interviews with both companies' CEOs. Geoffrey Dow from SXTP will discuss their FDA-approved antimalarial drug ARAKODA and plans to expand its use for diseases like babesiosis. Motti Farbstein from Can-Fite will present their oral drug platform targeting oncology and inflammatory diseases, along with updates on their late-stage clinical pipeline.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q3 2024 financial results showing significant year-over-year growth. Sales revenue increased 164% to $135 thousand, driven by a 140% increase in ARAKODA® pharmacy deliveries. The company achieved a gross profit of $24 thousand, compared to a $20 thousand loss in Q3 2023. However, operating expenses rose to $2.16 million, and net loss was $2.27 million. A $4 million private placement was completed at $1.38 per share. Key business developments included granting University of Kentucky reference rights for ARAKODA®, securing a U.S. Army contract, and advancing clinical trials for babesiosis treatment.
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has launched a nine-month promotional pilot for ARAKODA® (tafenoquine), an antimalarial medication. The pilot aims to increase brand awareness and utilization through virtual sales outreach and a co-pay assistance program. ARAKODA is the only FDA-approved prophylactic therapy that protects against all malaria stages, offering a convenient weekly dosing schedule.
The program includes virtual sales representatives conducting outreach to promote the co-pay program and boost sales. Data generated will inform the company on customer demographics, pricing, prescription trends, and guide future promotional efforts. This initiative precedes a planned expanded U.S. sales effort in 2025.
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has closed a $4 million private placement of common stock and warrants. The offering included 2,898,551 shares (or equivalents) at $1.38 per share, with accompanying series A and B warrants. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the proceeds for working capital, general operations, commercialization of Arakoda, and R&D. The securities were offered under Section 4(a)(2) of the Securities Act and have not been registered, limiting their sale in the United States.
FAQ
What is the current stock price of 60 degrees pharmaceuticals (SXTP)?
What is the market cap of 60 degrees pharmaceuticals (SXTP)?
